Glucose Levels During Gestational Diabetes Pregnancy and the Risk of Developing Postpartum Diabetes or Prediabetes

Chadakarn Phaloprakarn (chadakam_pt@yahoo.com)  
Faculty of Medicine Vajira Hospital, Navamindradhiraj University  
https://orcid.org/0000-0002-0925-2613

Siriwan Tangjitgamol  
Faculty of Medicine Vajira Hospital

Research article

Keywords: Gestational diabetes mellitus, Glucose level, Glycemic control, Postpartum prediabetes, Postpartum type 2 diabetes

DOI: https://doi.org/10.21203/rs.3.rs-91663/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Blood glucose levels during pregnancy may reflect the severity of insulin secretory defects and/or insulin resistance during gestational diabetes mellitus (GDM) pregnancy. We hypothesized that suboptimal glycemic control in women with GDM could increase the risk of postpartum type 2 diabetes mellitus (DM) or prediabetes. Our objective was to evaluate the impact of plasma glucose levels throughout GDM pregnancy on the risk of postpartum type 2 DM or prediabetes.

**Methods:** The medical records of 706 women with GDM who underwent a postpartum 75-g oral glucose tolerance test at our institution between January 2011 and December 2018 were reviewed. These women were classified into 2 groups according to glycemic control during pregnancy: \( \leq 1 \) occasion of either fasting glucose \( \geq 95 \text{ mg/dL} \) or 2-h postprandial glucose \( \geq 120 \text{ mg/dL} \) was defined as optimal glycemic control or else was classified as suboptimal glycemic control. Rates of postpartum type 2 DM and prediabetes were compared between women with optimal (n = 505) and suboptimal (n = 201) glycemic control.

**Results:** The rates of postpartum type 2 DM and prediabetes were significantly higher in the suboptimal glycemic control group than in the optimal glycemic control group: 22.4% vs. 3.0%, \( P < 0.001 \) for DM and 45.3% vs. 23.6%, \( P < 0.001 \) for prediabetes. In a multivariate analysis, suboptimal glucose control during pregnancy was an independent risk factor for developing either postpartum type 2 DM or prediabetes. The adjusted odds ratios were 18.9 (95% confidence interval, 7.0–50.7) for DM and 4.1 (95% confidence interval, 2.6–6.4) for prediabetes.

**Conclusion:** Our findings suggest that blood glucose levels during GDM pregnancy have an impact on the risk of postpartum type 2 DM and prediabetes.

Background

Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnancy that affects 20–25% of Southeast Asian pregnant women [1]. This metabolic derangement is characterized by insufficient insulin secretion from pancreatic \( \beta \)-cells to compensate for pregnancy-induced physiologic insulin resistance [2]. The coexistence of insulin secretory defects and insulin resistance can raise maternal blood glucose levels, resulting in adverse pregnancy outcomes. These coexisting disorders are also well recognized as important factors in the pathogenesis of prediabetes and type 2 diabetes mellitus (DM) [3, 4].

Good control of plasma glucose levels throughout gestation among pregnant women with GDM is generally recommended to minimize adverse pregnancy outcomes. Earlier studies have found increased risks of macrosomia and cesarean delivery among women with suboptimal or uncontrolled blood glucose levels compared to women with optimal glycemic control [5, 6]. Aside from pregnancy outcomes, an increased risk of postpartum glucose intolerance or type 2 DM in women with GDM who had poor glycemic control during pregnancy has been reported [7, 8]. However, the definition of ‘good or optimal’ vs.
‘poor or suboptimal’ glucose levels (using the 2-hour postprandial vs. mean daily glucose level) and the time points for the diagnosis or development of DM (weeks vs. years postpartum) are inconsistent among previous studies [7, 8].

Given that the levels of blood glucose during pregnancy may reflect the severity of insulin secretory defects and/or insulin resistance during GDM pregnancy [9], we hypothesized that suboptimal glycemic control in women with GDM would impart an increased risk of postpartum type 2 DM or prediabetes. The aim of this study was to determine the impact of glucose levels during GDM pregnancy on the risk of developing type 2 DM or prediabetes at 6 weeks postpartum. The criteria for optimal and suboptimal glycemic control were based on the standard recommendations of the American Diabetes Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG) that the fasting plasma glucose in GDM pregnancy should be maintained below 95 mg/dL and the 1-h or 2-h postprandial glucose below 140 mg/dL or 120 mg/dL, respectively [10, 11].

Methods

Participants

This retrospective study was performed at Faculty of Medicine Vajira Hospital, which is a 800-bed tertiary care and referral hospital located in Bangkok, Thailand. Medical records of women with a diagnosis of GDM who delivered and returned to our institution between January 2011 and December 2018 for a 75-g oral glucose tolerance test (OGTT) at 6 weeks postpartum were reviewed. Women with a diagnosis of pregestational DM and those without available data on fasting and/or postprandial plasma glucose levels during pregnancy were excluded from the study.

Blood glucose testing and diagnosis

As a standard practice in our institution, all pregnant women without risk factors for GDM underwent a glucose challenge test (GCT) at 24–28 weeks of gestation. On the other hand, women with risk factors received a screening test at the initial visit and, if negative, were rescreened at 28–32 weeks of gestation. Individuals with a GCT result of 140 mg/dL or higher would be scheduled for a diagnostic 100-g OGTT. The diagnosis of GDM was based on the Carpenter and Coustan criteria [12].

The management of women with GDM included dietary and lifestyle modifications as initial treatment. These women were evaluated for their levels of glycemic control throughout gestation by the measurement of fasting and 2-h postprandial plasma glucose levels every 2–4 weeks. Insulin therapy was determined and prescribed by an endocrinologist according to the blood glucose level control.

Optimal or suboptimal control of plasma glucose levels was defined according to the thresholds for fasting and 2-h postprandial glucose recommended by the ADA and ACOG [10, 11]. Optimal glycemic control was defined as no more than one occasion of either a fasting glucose level of at least 95 mg/dL or a 2-h postprandial glucose level of at least 120 mg/dL. Suboptimal glycemic control was defined as
two or more occasions of a fasting glucose level of at least 95 mg/dL and/or a 2-h postprandial glucose level of at least 120 mg/dL.

After delivery, all women with a diagnosis of GDM were scheduled for a 75-g OGTT at 6 weeks postpartum.

Data collection and study outcome

The data collected included age, parity, prepregnancy body mass index (BMI), history of DM in any first-degree relatives, GCT and 100-g OGTT values, gestational age at GDM diagnosis, insulin use (type and dose), fasting and 2-h postprandial glucose levels throughout pregnancy, neonatal birth weight, and postpartum 75-g OGTT values.

The primary study outcome was the development of type 2 DM or prediabetes at 6 weeks postpartum. The diagnosis of DM was a level of fasting plasma glucose of at least 126 mg/dL or a plasma glucose level of at least 200 mg/dL at 2 h after a 75-g OGTT [11]. A fasting plasma glucose level of 100–125 mg/dL or a 2-h glucose level of 140–199 mg/dL was referred to as impaired fasting glucose or impaired glucose tolerance, respectively. The diagnosis of prediabetes included either impaired fasting glucose or impaired glucose tolerance or both [11].

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corporation, Armonk, NY, USA). Categorical variables are described as numbers and percentages and were compared by the chi-square test or Fisher’s exact test as appropriate. Continuous variables are reported as the median and interquartile range and were compared with the Mann-Whitney U test. The odds ratios (ORs) with 95% confidence intervals (CIs) of type 2 DM and prediabetes of suboptimal glycemic control were analyzed by multivariate logistic regression and adjusted for potential confounders. The predictive performance of suboptimal glycemic control during pregnancy for postpartum type 2 DM or prediabetes was determined by the receiver operating characteristic (ROC) curve. A value of \( P < 0.05 \) was considered statistically significant.

Ethical approval

This study was approved by the Vajira Institution Review Board (certificate of approval no.138/2561) and was performed in compliance with the Declaration of Helsinki.

Results

Characteristics of the study population

A total of 706 women with GDM who had available data on plasma glucose levels during pregnancy and a postpartum 75-g OGTT were included for analysis. Of these, 505 (71.5%) women had optimal blood
glucose control, and 201 (28.5%) had suboptimal glucose control during pregnancy. The baseline characteristics of women with optimal and suboptimal glycemic control are presented in Table 1. Rates of multiparity, overweight or obese BMI ($\geq 25 \text{ kg/m}^2$), history of DM in any first-degree relatives, and insulin use were significantly higher among women with suboptimal glycemic control than those with optimal glycemic control. The women with suboptimal glycemic control also had significantly higher median prepregnancy BMI, GCT, fasting, 1-h and 2-h OGTT values, units of insulin used, and neonatal birth weight but a significantly lower gestational age at GDM diagnosis.

**Rates of postpartum type 2 DM and prediabetes**

The rates of postpartum type 2 DM and prediabetes in women who had suboptimal blood glucose control during pregnancy were significantly higher than those in women with optimal blood glucose control: 22.4% vs. 3.0% for DM and 45.3% vs. 23.6% for prediabetes, $P < 0.001$ for both (Table 2).

After adjustment for potential confounding factors (parity, prepregnancy BMI, history of DM in any first-degree relatives, GCT and 100-g OGTT glucose values), suboptimal glucose control during pregnancy was an independent risk factor for developing either postpartum type 2 DM or prediabetes. The adjusted ORs were 18.9 (95% CI, 7.0–50.7) for DM and 4.1 (95% CI, 2.6–6.4) for prediabetes. Women with suboptimal control of either fasting or postprandial glucose during pregnancy had a lower OR for developing either DM or prediabetes than women with suboptimal control of both fasting and postprandial glucose levels: 3.7 (95% CI, 2.1–6.6) vs. 5.9 (95% CI, 3.5–10.1).

**Comparison of different glucose thresholds for suboptimal glycemic control**

We also compared the predictive performances of postpartum type 2 DM or prediabetes of the three different glucose thresholds for suboptimal glycemic control: the thresholds being used in the present study (recommended by the ADA and ACOG), the threshold using any 2-hour postprandial glucose level of 150 mg/dL or higher [7] and the threshold using a mean daily glucose of more than 95 mg/dL [8]. The glucose thresholds recommended by the ADA and ACOG yielded the best predictive performance with an area under the ROC curve of 0.677 (95% CI 0.635–0.720), followed by the threshold using a mean daily glucose of more than 95 mg/dL [8] and the threshold using any 2-hour postprandial glucose level of 150 mg/dL or higher [7] (Fig. 1). The sensitivities, specificities, positive predictive values, negative predictive values, and area under the ROC curves of the three predictive criteria are presented in Table 3.

**Discussion**

The findings of this study indicated that blood glucose levels throughout pregnancy of women with GDM were directly related to the risk of developing type 2 DM or prediabetes at 6 weeks postpartum. This association was independent of the glucose levels measured at the time of GDM diagnosis, as assessed by the 100-g OGTT values. Our observation suggests that not merely the presence of GDM, which is a well-known risk factor for type 2 DM [13], but also glycemic control plays an important role in modifying the risk of postpartum DM as well as prediabetes. Pregnant women with GDM should be educated about
the benefits and targets of optimal glycemic control to decrease both intra- and postpartum adverse effects. Regular monitoring of plasma glucose levels and timely initiation of insulin therapy should be considered to maintain adequate glycemic control throughout pregnancy.

Furthermore, we found a direct association between the degree of suboptimal glycemic control, as characterized by the pattern of elevated fasting and postprandial glucose levels, and the development of DM or prediabetes postpartum. Risks of postpartum DM or prediabetes were increased by 3.7-fold among women with suboptimal control of either fasting or postprandial glucose and 5.9-fold among women with suboptimal control of both fasting and postprandial glucose compared to women with optimal glycemic control.

Two hypotheses have been proposed to explain the association between suboptimal glycemic control during GDM pregnancy and the development of postpartum type 2 DM or prediabetes. First, this may be related to the severity of chronic β-cell dysfunction and insulin resistance that manifests as hyperglycemia in pregnancy [9, 14, 15] and translates into a continuum of dysglycemia (prediabetes and type 2 DM) in the postpartum period or later in life [14, 15]. Saisho et al. [9], who used the disposition index to evaluate β-cell dysfunction, found an association of the level of β-cell dysfunction with the severity of glucose intolerance (assessed by the fasting and mean daily blood glucose levels) during pregnancy among Japanese women with GDM. Other authors also observed a correlation between the degree of glucose intolerance in pregnancy and the magnitudes of β-cell dysfunction and insulin resistance in Western pregnant women [14, 15]. Given that insulin secretory defects and insulin resistance are well recognized as precursors of type 2 DM and prediabetes [3, 4], the risk of developing either type of glucose intolerance postpartum was therefore higher in women with a more severe degree of suboptimal glycemic control during pregnancy than in those with a lesser extent of suboptimal glycemic control.

The second hypothesis is that chronic exposure of pancreatic islets to elevated glucose levels during pregnancy exerts toxicity on β-cells by oxidative stress, leading to more β-cell dysfunction and cell death and consequent prediabetes or type 2 DM after pregnancy [16, 17]. These cascade events were demonstrated in several studies that found a reduction in β-cell volume among patients with type 2 DM compared to nondiabetic subjects [18–21]. Nevertheless, such prior studies were limited by being a cross-sectional research design and not being conducted in vivo. Further longitudinal studies are therefore needed to compare the changes in β-cell mass over time from antepartum to postpartum among women with GDM who develop and do not develop postpartum DM or prediabetes.

Given that there have been no recommendations from the expert panels regarding plasma glucose thresholds during pregnancy that are related to a reduced risk of postpartum DM or prediabetes, we then adopted the fasting and postprandial glucose targets, as recommended by the ADA and ACOG to reduce the risk of macrosomia [10, 11], to classify the plasma glucose levels of women in this study as indicating optimal or suboptimal glycemic control. Previous studies have reported that intermittent high glucose levels rather than persistent hyperglycemia stimulate reactive oxygen species overproduction, β-cell apoptosis and dysfunction [22–24]. Hence, we focused on high blood glucose levels at different time
points in preference over high mean blood glucose levels. With a fasting glucose level of 95 mg/dL or higher and/or 2-h postprandial glucose of 120 mg/dL or higher on at least two occasions, the predictive performance of these glucose thresholds for postpartum DM or prediabetes yielded moderate discriminatory power (an area under the ROC curve of 0.677). Aside from these glucose thresholds, two other studies that used different glucose thresholds to define suboptimal glycemic control during pregnancy also reported an increased risk of postpartum glucose intolerance or future type 2 DM among women with suboptimal glycemic control [7, 8]. When a comparison among the three glucose thresholds was made, we found that the thresholds used in our study yielded the best predictive performance for type 2 DM or prediabetes at 6 weeks postpartum. Our findings suggested that the fasting and 2-h postprandial glucose targets recommended by the ADA and ACOG to reduce the risk of macrosomia could also lessen the risk of developing postpartum DM or prediabetes.

Aside from type 2 DM, we also paid attention to the development of prediabetes because this metabolic state represents an intermediate hyperglycemic state for progression to type 2 DM [25]. As the lifetime risk of progressing from prediabetes to DM has been reported to be high at 74% [26], a reduced risk of postpartum prediabetes should be as important as that of type 2 DM. This study found that both spectra of glucose intolerance were significantly decreased with optimal glycemic control.

Notably, the present study focused specifically on the development of dysglycemia in the early postpartum period. Although data on the long-term impact of glycemic control during pregnancy on glucose intolerance are interesting, we were aware of other factors that may influence the risk of subsequent type 2 DM or prediabetes, such as diet and physical activity. A well-designed prospective study controlling all relevant factors with a long-term follow-up may be able to provide a definite answer regarding an association of glycemic control during pregnancy and the long-term risk of dysglycemia.

The strength of our study included having a large number of pregnant women with multiple fasting and postprandial blood glucose measurements throughout pregnancy. In addition, all blood glucose specimens collected in our institution were measured using the same automated glucose analyzer, which was calibrated regularly to obtain accurate results. Furthermore, the diagnoses of GDM and postpartum DM or prediabetes were made according to the standard guidelines. Nevertheless, there are a few limitations that one should bear in mind when applying our results in clinical practice. Although the mean blood glucose level may be more accurate in representing optimal or suboptimal blood glucose control, most women, especially those in limited-resource settings, may be unable to comply with frequent self-monitoring of their blood glucose levels. We therefore suggest a regular blood glucose measurement in the hospital to define optimal or suboptimal glycemic control. Second, our study was limited by being conducted in a single institution and by the use of Carpenter and Coustan criteria to diagnose GDM. We cannot confirm the generalizability of our results until further prospective studies are carried out in different settings.

Conclusion
Our study demonstrated that glucose levels during GDM pregnancy have an impact on the risk of developing type 2 DM or prediabetes at 6 weeks postpartum. Optimal glycemic control throughout pregnancy is therefore necessary to reduce these risks. Aside from weight loss and insulin therapy that can temporarily improve β-cell function, future research is needed to search for interventions that can permanently arrest the progression of β-cell dysfunction in women with GDM.

**Abbreviations**

ACOG: American College of Obstetricians and Gynecologists; ADA: American Diabetes Association; DM: diabetes mellitus; GCT: glucose challenge test; GDM: gestational diabetes mellitus; OGTT: oral glucose tolerance test

**Declarations**

**Acknowledgements**

Not Applicable.

**Authors’ contributions**

CP: study design, data collection and interpretation, manuscript writing, proof and validation; and ST: manuscript writing, proof and validation. All authors have critically revised the manuscript and approved the final version.

**Funding**

This work was supported by the Navamindradhiraj University Research Fund.

**Availability of data and materials**

The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Vajira Institution Review Board (certificate of approval no.138/2561). Permission to access the data was granted by the dean of the Faculty of Medicine Vajira Hospital.

**Consent for publication**

Not Applicable.

**Competing interests**

All authors declare that they have no competing interest.
References

1. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16:7.

2. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19:3342.

3. Lorenzo C, Wagenknecht LE, D’Agostino RB Jr, Rewers MJ, Karter AJ, Haffner SM. Insulin resistance, β-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: The insulin resistance atherosclerosis study. Diabetes Care. 2010;33:67–72.

4. Tura A, Göbl C, Moro E, Pacini G. Insulin resistance and beta-cell dysfunction in people with prediabetes according to criteria based on glycemia and glycosylated hemoglobin. Endocr J. 2017;64:117–22.

5. González-Quintero VH, Istwan NB, Rhea DJ, Rodriguez LI, Cotter A, Carter J, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care. 2007;30:467–70.

6. Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD. Arrendondo F.

7. Intensified versus conventional. management of gestational diabetes. Am J Obstet Gynecol. 1994;170:1036–46.

8. Greenberg LR, Moore TR, Murphy H. Gestational diabetes mellitus: antenatal variables as predictors of postpartum glucose intolerance. Obstet Gynecol. 1995;86:97–101.

9. Yefet E, Schwartz N, Sliman B, Ishay A, Nachum Z. Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: a retrospective cohort study. Cardiovasc Diabetol. 2019;18:75.

10. Saisho Y, Miyakoshi K, Tanaka M, Shimada A, Ikenoue S, Kadohira I, et al. Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J. 2010;57:973–80.

11. American Diabetes Association. 14. Management of diabetes in pregnancy: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S183–S92.

12. Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol. 2018;131:e49–64.

13. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768–73.

14. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.

15. Kramer CK, Swaminathan B, Hanley AJ, Connelly PW, Sermer M, Zinman B, et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. Diabetes Care. 2014;37:3262–9.

16. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care. 2008;31:2026–31.
17. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.
18. Saisho Y. β-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6:109–24.
19. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300–8.
20. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45:85–96.
21. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl 4):32–42.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10.
23. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52:2795–804.
24. Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006;22:198–203.
25. Shao C, Gu J, Meng X, Zheng H, Wang D. Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells. Int J Clin Exp Med. 2015;8:5462–9.
26. Hostalek U. Global epidemiology of prediabetes - present and future perspectives. Clin Diabetes Endocrinol. 2019;5:5.
27. Ligthart S, van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:44–51.

Tables

Table 1 Characteristics of women with optimal and suboptimal glycemic control
| Characteristic                                      | Optimal glycemic control | Suboptimal glycemic control | $P$  |
|----------------------------------------------------|---------------------------|-----------------------------|------|
|                                                   | $(n = 505)$               | $(n = 201)$                 |      |
| Age (years)                                       | 32.0 (28.0–36.0)         | 33.0 (28.0–37.0)            | 0.514|
| $\geq$ 35 years old                               | 190 (37.6)               | 82 (40.8)                   | 0.434|
| Multiparity                                        | 294 (58.2)               | 149 (74.1)                  | $< 0.001$|
| Prepregnancy BMI (kg/m$^2$)                        | 22.6 (20.4–25.7)         | 26.3 (23.0–30.7)            | $< 0.001$|
| Overweight or obese BMI ($\geq$ 25 kg/m$^2$)       | 146 (28.9)               | 119 (59.2)                  | $< 0.001$|
| History of DM in any first-degree relatives        | 135 (26.7)               | 69 (34.3)                   | 0.045|
| GCT value (mg/dL)                                 | 164.0 (152.0–182.0)      | 177.0 (156.5–210.0)         | $< 0.001$|
| 100-g OGTT (mg/dL)                                 |                          |                             |      |
| Fasting value                                      | 82.0 (75.0–88.8)         | 96.0 (88.0–106.0)           | $< 0.001$|
| 1-h value                                          | 191.0 (180.0–204.0)      | 207.0 (191.0–232.0)         | $< 0.001$|
| 2-h value                                          | 173.0 (160.0–188.0)      | 183.0 (167.0–213.0)         | $< 0.001$|
| 3-h value                                          | 146.5 (127.0–160.0)      | 148.0 (125.0–174.0)         | 0.134|
| Gestational age at GDM diagnosis (weeks)           | 29.0 (17.0–31.0)         | 18.5 (10.0–29.0)            | $< 0.001$|
| Insulin use                                        | 12 (2.4)                 | 82 (40.8)                   | $< 0.001$|
| Type of insulin                                    |                           |                             |      |
| Rapid-acting insulin                               | 1 (0.2)                  | 10 (5.0)                    | $< 0.001$|
| Short-acting insulin                               | 0 (0)                    | 22 (10.9)                   | $< 0.001$|
| Intermediate-acting insulin                        | 4 (0.8)                  | 20 (10.0)                   | $< 0.001$|
| Premixed insulin                                   | 8 (1.6)                  | 51 (25.4)                   | $< 0.001$|
| Units of insulin used in pregnancy                 | 333 (130–411)            | 946 (303–1758)              | 0.006|
Average plasma glucose during pregnancy (mg/dL)

|                          | Fasting value                  | 2-h postprandial value | Neonatal birth weight (g) |
|--------------------------|--------------------------------|------------------------|---------------------------|
|                          | 78.9 (74.0–84.0)               | 92.5 (84.6–100.9)      | 3220 (2905–3549)          |
|                          | 92.5 (84.6–100.9)              | 119.5 (111.4–132.5)    | 3516 (3039–3840)          |

Data are expressed as the median (IQR) or n (%).

BMI: body mass index; DM: diabetes mellitus; GCT: glucose challenge test; GDM: gestational diabetes mellitus; IQR: interquartile range; OGTT: oral glucose tolerance test

### Table 2 Risks of postpartum type 2 diabetes mellitus or prediabetes in women with optimal and suboptimal glycemic control

| Glucose control                          | Postpartum risk                      |
|------------------------------------------|--------------------------------------|
|                                           | Either type 2 DM or prediabetes (n = 270) | Type 2 DM (n = 60) | Prediabetes (n = 210) |
|                                          | n (%) | Adjusted OR<sup>a</sup> | n (%) | Adjusted OR<sup>a</sup> | n (%) | Adjusted OR<sup>a</sup> |
|                                          |       |                           |       |                           |       |                           |
|                                          |       | (95% CI)                  |       | (95% CI)                  |       | (95% CI)                  |
| Optimal glycemic control (n = 505)       | 134/505 (26.5) | 1.0 (reference) | 15/505 (3.0) | 1.0 (reference) | 119/505 (23.5) | 1.0 (reference) |
| Suboptimal glycemic control (n = 201)    | 136/201 (67.7) | 4.9 (3.2–7.4) | 45/201 (22.4) | 18.9 (7.0–50.7) | 91/201 (45.3) | 4.1 (2.6–6.4) |
| Pattern of suboptimal glycemic control   |       |                           |       |                           |       |                           |
| Either fasting or postprandial glucose   | 39/66 (59.1) | 3.7 (2.1–6.6) | 4/66 (6.1) | 4.1 (0.8–20.1) | 35/66 (53.0) | 3.7 (2.1–6.7) |
| (n = 66)                                 |       |                           |       |                           |       |                           |
| Both fasting and postprandial glucose    | 97/135 (71.9) | 5.9 (3.5–10.1) | 41/135 (30.4) | 32.1 (10.7–95.8) | 56/135 (41.5) | 4.5 (2.6–8.1) |

<sup>a</sup>Adjusted for parity, prepregnancy BMI, history of DM in any first-degree relatives, GCT and 100-g OGTT glucose values.
Table 3 Predictive performance for postpartum type 2 diabetes mellitus or prediabetes according to the three criteria for defining suboptimal glycemic control

| Criteria                                 | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | PPV (%) (95% CI) | NPV (%) (95% CI) | AUC (95% CI)   |
|------------------------------------------|--------------------------|--------------------------|------------------|------------------|----------------|
| The present study\(^a\)                  | 50.4 (44.3–56.5)         | 85.1 (81.4–88.3)         | 67.7 (61.9–73.0) | 73.5 (68.3–75.1) | 0.677 (0.635–0.720) |
| Any 2-h postprandial glucose ≥ 150 mg/dL | 26.7 (21.5–32.4)         | 92.2 (89.3–94.5)         | 67.9 (59.2–75.6) | 67.0 (65.3–68.7) | 0.594 (0.550–0.639) |
| Mean daily glucose > 95 mg/dL            | 55.2 (49.0–61.2)         | 74.1 (69.7–78.1)         | 56.9 (52.1–61.5) | 72.8 (69.8–75.5) | 0.646 (0.604–0.689) |

\(^a\)The criteria for defining suboptimal glycemic control used in the present study were ≥ 2 occasions of fasting glucose ≥ 95 mg/dL and/or 2-h postprandial glucose ≥ 120 mg/dL.

AUC: area under the receiver operating characteristic curve; CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value